Cargando…

Non-alcoholic fatty liver disease and liver secretome

Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysreg...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Muhammad Sohaib, Lee, Choongho, Kim, Sang Geon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Pharmaceutical Society of Korea 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703441/
https://www.ncbi.nlm.nih.gov/pubmed/36441472
http://dx.doi.org/10.1007/s12272-022-01419-w
_version_ 1784839849470066688
author Khan, Muhammad Sohaib
Lee, Choongho
Kim, Sang Geon
author_facet Khan, Muhammad Sohaib
Lee, Choongho
Kim, Sang Geon
author_sort Khan, Muhammad Sohaib
collection PubMed
description Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysregulation, endoplasmic reticulum stress, and insulin resistance may cause disturbances in the secretion of the proteins from the liver and their physiologic modifications and interactions with others. Since the liver secretome plays a role in the regulation of fuel metabolism and inflammation not only in the liver per se but also in other organs, the proteins belong to the utmost targets for treating metabolic and inflammatory diseases (e.g., COVID-19), depending on the available and feasible approaches to controlling their biological effects. However, in this era, we still come across new liver-derived proteins but are yet unable to entirely understand the pathologic basis underlying disease progression. This review aims to provide an updated overview of liver secretome biology with explanatory mechanisms with regard to the progression of metabolic and inflammatory liver diseases.
format Online
Article
Text
id pubmed-9703441
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Pharmaceutical Society of Korea
record_format MEDLINE/PubMed
spelling pubmed-97034412022-11-28 Non-alcoholic fatty liver disease and liver secretome Khan, Muhammad Sohaib Lee, Choongho Kim, Sang Geon Arch Pharm Res Review Metabolism of carbohydrates and lipids and protein degradation occurs in the liver and contributes to the body's homeostasis by secreting a variety of mediators. Any imbalance in this homeostasis due to excess fat consumption and the pathologic events accompanying lipotoxicity, autophagy dysregulation, endoplasmic reticulum stress, and insulin resistance may cause disturbances in the secretion of the proteins from the liver and their physiologic modifications and interactions with others. Since the liver secretome plays a role in the regulation of fuel metabolism and inflammation not only in the liver per se but also in other organs, the proteins belong to the utmost targets for treating metabolic and inflammatory diseases (e.g., COVID-19), depending on the available and feasible approaches to controlling their biological effects. However, in this era, we still come across new liver-derived proteins but are yet unable to entirely understand the pathologic basis underlying disease progression. This review aims to provide an updated overview of liver secretome biology with explanatory mechanisms with regard to the progression of metabolic and inflammatory liver diseases. Pharmaceutical Society of Korea 2022-11-28 2022 /pmc/articles/PMC9703441/ /pubmed/36441472 http://dx.doi.org/10.1007/s12272-022-01419-w Text en © The Pharmaceutical Society of Korea 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review
Khan, Muhammad Sohaib
Lee, Choongho
Kim, Sang Geon
Non-alcoholic fatty liver disease and liver secretome
title Non-alcoholic fatty liver disease and liver secretome
title_full Non-alcoholic fatty liver disease and liver secretome
title_fullStr Non-alcoholic fatty liver disease and liver secretome
title_full_unstemmed Non-alcoholic fatty liver disease and liver secretome
title_short Non-alcoholic fatty liver disease and liver secretome
title_sort non-alcoholic fatty liver disease and liver secretome
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9703441/
https://www.ncbi.nlm.nih.gov/pubmed/36441472
http://dx.doi.org/10.1007/s12272-022-01419-w
work_keys_str_mv AT khanmuhammadsohaib nonalcoholicfattyliverdiseaseandliversecretome
AT leechoongho nonalcoholicfattyliverdiseaseandliversecretome
AT kimsanggeon nonalcoholicfattyliverdiseaseandliversecretome